Octapharma scientific, medical, and patient support teams all around the world are hard at work on ways to treat the effects of COVID-19.
In the fight against coronavirus, there is an unprecedented global effort to develop solutions for patients who suffer from this disease. Octapharma is at the forefront, applying our extensive expertise in blood plasma and immunoglobulins, both intravenous (IVIg) and subcutaneous (SCIg), to investigate a potential COVID-19 treatment. We are actively investigating the use of readily-available IVIg products for COVID-19 treatment. High-dose IVIg is typically used as an immunomodulatory agent for an increasing number of immune and inflammatory disorders across various clinical specialties.1 Early research indicates the possibility of IVIg to improve the prognosis of severe and critically ill patients with COVID-19. We are also working with other partners to obtain convalescent plasma (CP), plasma derived from previously infected but now disease-free donors, for development of an investigational, hyper-immune therapy.
Octapharma USA Presents Results of Investigational Use of Octagam® 10% for Severe COVID-19 Patients at ASH Annual Meeting
Intravenous Immunoglobulin Significantly Reduces Respiratory Morbidity in COVID-19 Study Supported by Octapharma
Octapharma USA and BioMatrix Support Research Study Focused on COVID-19 and Myocardial Dysfunction
News 12 New Jersey
Rich Walters, Octapharma USA Commercial Development Senior VP talks about IVIg Investigative Trials
FDA approves Octapharma USA investigational new drug application for severe COVID-19 patients
Wall Street Journal
Researchers Explore Using Common Blood-Plasma Treatment to Fight Coronavirus
From safeguarding the health of our employees, patients and partners, to exploring new applications for existing therapies while developing new treatments, to assuring the availability of our therapies to those who need them, Octapharma has mobilized to respond to the COVID-19 pandemic on every front.Learn More
Octapharma is collaborating with global leaders in plasma fractionation to develop a new plasma-derived immunoglobulin therapy to treat COVID-19. This collaboration, called the CoVIg-19 Plasma Alliance, will leverage leading-edge expertise and work that companies including Octapharma, CSL, Takeda, BPL, Biotest, LFB, ADMA Biologies, BioPharma Plasma, GC Pharma and Sanquin have underway.Learn More